杨胜勇 - 四川大学 - 生物治疗国家重点实验室

个人简介

1999年毕业于四川大学化学学院，获物理化学专业博士学位。1999年-2001年，香港科技大学化学系博士后。2002年12月-2005年10月，加拿大Calgary大学Research Scientist。2005年10月通过985平台进入四川大学华西医院生物治疗国家重点实验室工作。主持了包括863计划、国家创新药物重大专项、国家自然科学基金、教育部新世纪优秀人才资助计划等多项国家和省部级项目。

研究领域

（1）药物分子设计新方法研究（2）小分子靶向药物设计、合成与先导化合物优化研究（3）化学生物学（4）针对肿瘤等重大疾病的一类新药的研究与开发

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY*. Structure-Activity Relationship Studies of Pyrazolo[3,4-d]Pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity Against Acute Myeloid Leukemia in Vitro and in Vivo. J Med Chem, 2013, 56(4): 1641-1655. 2. Li GB,Yang LL, Wang WJ, Li LL,Yang SY*. ID-Score: A New Empirical Scoring Function Based on a Comprehensive Set of Descriptors Related to Protein−Ligand Interactions. J Chem Inf Model, 2013, 53(3): 592–600. 3. Cao ZX, Liu JJ, Zheng RL, Yang J, Zhong L, Xu Y, Wang LJ, Zhang CH, Wang BL, Ma S, Wang ZR, Xie HZ, Wei YQ, Yang SY*. SKLB1028, a Novel Oral Multikinase Inhibitor of EGFR, FLT3 and Abl, Displays Exceptional Activity in Models of FLT3-driven AML and Considerable Potency in Models of CML Harboring Abl Mutants. Leukemia, 2012, 26(8): 1892-1895. 4. Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, Xu Y, Ji P, Zhang CH, Wang WJ, Lin XD, Li LL, Wei YQ, Yang SY*. Structural Optimization and Structure-Activity Relationships of N-2-(4-(4-Methylpiperazin- 1-yl)phenyl)- N-8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations. J Med Chem, 2012, 55(23): 10685-10699. 5. Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY*. Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3-Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl }-3-ptolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in Vitro and in Vivo. J Med Chem, 2012, 55(8): 3852-3866. 6. Pan YL, Xu Y, Feng S, Luo SD, Zheng RL, Yang J, Wang LJ, Zhong L, Yang HY, Wang BL, Yu Y, Liu JJ, Cao ZX, Wang XY, Ji P, Wang ZR, Chen X, Zhang S, Wei YQ, Yang SY*. SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo. Mol Cancer Ther, 2012, 11(4): 952-962. 7. Zhang S, Cao ZX, Tian HW, Shen GB, Ma YP, Xie HZ, Liu YL, Zhao CJ, Deng SY, Yang Y, Zheng RL, Li WW, Zhang N, Liu SY, Wang W, Dai LX, Shi S, Cheng L, Pan YL, Feng S, Zhao X, Deng HX*, Yang SY*, Wei YQ. SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo. Clin Cancer Res, 2011, 17(13): 4439-4450. 8. Ren JX, Li LL, Zheng RL, Xie HZ, Cao ZX, Feng S, Pan YL, Chen X, Wei YQ, Yang SY*. Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking. J Chem Inf Model, 2011, 51(6): 1364-1375. 9. Huang Q, Li LL, Yang SY*. RASA: A Rapid Retrosynthesis-Based Scoring Method for the Assessment of Synthetic Accessibility of Drug-like Molecules. J Chem Inf Model, 2011, 51(10): 2768-2777. 10. Yang SY*. Pharmacophore Modeling and Applications in Drug Discovery: Challenges and Recent Advances. Drug Discov Today, 2010, 15(11-12): 444-450.